These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27558933)

  • 1. The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6.
    Boschert V; Frisch C; Back JW; van Pee K; Weidauer SE; Muth EM; Schmieder P; Beerbaum M; Knappik A; Timmerman P; Mueller TD
    Open Biol; 2016 Aug; 6(8):. PubMed ID: 27558933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097.
    Boschert V; Muth EM; Knappik A; Frisch C; Mueller TD
    Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):388-92. PubMed ID: 25849496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition.
    Boschert V; van Dinther M; Weidauer S; van Pee K; Muth EM; Ten Dijke P; Mueller TD
    PLoS One; 2013; 8(11):e81710. PubMed ID: 24312339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
    van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
    PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6.
    Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG
    Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.
    Holdsworth G; Slocombe P; Doyle C; Sweeney B; Veverka V; Le Riche K; Franklin RJ; Compson J; Brookings D; Turner J; Kennedy J; Garlish R; Shi J; Newnham L; McMillan D; Muzylak M; Carr MD; Henry AJ; Ceska T; Robinson MK
    J Biol Chem; 2012 Aug; 287(32):26464-77. PubMed ID: 22696217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains.
    Kim J; Han W; Park T; Kim EJ; Bang I; Lee HS; Jeong Y; Roh K; Kim J; Kim JS; Kang C; Seok C; Han JK; Choi HJ
    Nat Commun; 2020 Oct; 11(1):5357. PubMed ID: 33097721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling.
    Shum KT; Chan C; Leung CM; Tanner JA
    Biochem J; 2011 Mar; 434(3):493-501. PubMed ID: 21204783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors.
    Choi J; Lee K; Kang M; Lim SK; Tai No K
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1116-1121. PubMed ID: 29486968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin's endocrine effects on body composition and glucose metabolism.
    Kim SP; Da H; Li Z; Kushwaha P; Beil C; Mei L; Xiong WC; Wolfgang MJ; Clemens TL; Riddle RC
    J Biol Chem; 2019 Apr; 294(17):6899-6911. PubMed ID: 30842262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR structure of the Wnt modulator protein Sclerostin.
    Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD
    Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting highly structure-specific antibodies using structured synthetic mimics of the cystine knot protein sclerostin.
    Back JW; Frisch C; Van Pee K; Boschert V; van Vught R; Puijk W; Mueller TD; Knappik A; Timmerman P
    Protein Eng Des Sel; 2012 May; 25(5):251-9. PubMed ID: 22454505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemorrhagic snake venom metalloproteases and human ADAMs cleave LRP5/6, which disrupts cell-cell adhesions in vitro and induces haemorrhage in vivo.
    Seo T; Sakon T; Nakazawa S; Nishioka A; Watanabe K; Matsumoto K; Akasaka M; Shioi N; Sawada H; Araki S
    FEBS J; 2017 Jun; 284(11):1657-1671. PubMed ID: 28425175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
    Rujas E; Gulzar N; Morante K; Tsumoto K; Scott JK; Nieva JL; Caaveiro JM
    J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
    Covaceuszach S; Cattaneo A; Lamba D
    Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
    Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
    J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.